Islet Amyloid Polypeptide Analogues with Reduced Aggregation: Implications for Type 2 Diabetes
Endocrines · 09.06.2026 · 7 (2) · 28
DOI: 10.3390/endocrines7020028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrines, online erschienen am 09.06.2026. Verfasst von Shahab Hassan und 6 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: London Metropolitan University, Biotechnology and Biological Sciences Research Council, Wellcome Trust.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes is projected to affect millions of people annually as the number of cases rises year on year. This includes children. Treating diabetes and its related comorbidities has a huge economic impact and puts pressure on healthcare providers. Understanding the disease at a molecular level is key for developing better therapeutics. The protein Islet Amyloid Polypeptide (IAPP) or amylin is important for glucose regulation; however, it is also instrumental in type 2 diabetes pathology. Human IAPP can misfold into oligomers and amyloid fibrillar aggregates within pancreatic islets, promoting β-cell dysfunction and death, contributing to progressive insulin deficiency and worsening hyperglycaemia.
Methods
Based on previous studies on mutations at residues 18, 28 and 31,we have designed three novel IAPP analogues (two double and one triple mutant) to assess whether the combined amino acid substitutions impact fibril formation, solubility and toxicity.
Results
All three of our analogues show a reduced propensity to aggregate and are more soluble than wild type IAPP. Compared with pramlintide, a clinically prescribed synthetic analogue of human amylin, all of our analogues appeared to have similarly reduced toxicity and improved solubility relative to human IAPP. Additionally, two of our analogues exhibited a markedly slower rate of fibril formation.
Conclusions
Our results highlight the importance of targeting multiple residues as a promising strategy for developing improved diabetes therapeutics in the future.
Förderung
- London Metropolitan University
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- British Heart Foundation
Zitieren
APA
Hassan, S., Evans, S. L., Torpey, J. H., Bui, T., Isaacson, R. L., White, K., & Terry, C. (2026). Islet Amyloid Polypeptide Analogues with Reduced Aggregation: Implications for Type 2 Diabetes. Endocrines, 7(2), 28. https://doi.org/10.3390/endocrines7020028
Vancouver
Hassan S, Evans SL, Torpey JH, Bui T, Isaacson RL, White K, et al. Islet Amyloid Polypeptide Analogues with Reduced Aggregation: Implications for Type 2 Diabetes. Endocrines. 2026;7(2):28. doi:10.3390/endocrines7020028
BibTeX
@article{Hassan2026,
author = {Hassan, Shahab and Evans, Sasha L. and Torpey, James H. and Bui, Tam and Isaacson, Rivka L. and White, Kenneth and Terry, Cassandra},
title = {Islet Amyloid Polypeptide Analogues with Reduced Aggregation: Implications for Type 2 Diabetes},
journal = {Endocrines},
year = {2026},
volume = {7},
number = {2},
pages = {28},
doi = {10.3390/endocrines7020028}
}
EUVIMED